Orakl has developed an AI‑powered techbio platform that combines real‑world patient data with biology into an integrated decision‑making engine for the entire drug development process. Its technology delivers predictions to improve recruitment of responding patients and increase clinical trial probability of success, and the company develops ex vivo patient avatars for therapeutic decision‑making. The newly raised capital will accelerate the company’s growth and support the commercial launch of two products, O‑Predict and O‑Validate. Orakl also plans to use the platform to inform in‑licensing decisions and to build its own internal pipeline. The company was founded in 2023 by Fanny Jaulin, PhD, Diane‑Laure Pagès, PhD, and Gustave Ronteix, PhD, as a spin‑off from the Gustave Roussy Institute. It positions itself to de‑risk clinical trials and expedite the availability of new transformative medicines in precision oncology. Orakl Oncology develops a techbio platform that integrates best-in-class biology with high-quality clinical and molecular real-world patient data to model tumors and predict drug responses. The company builds scalable, patient-specific tumor avatars that capture cancer heterogeneity to help pharma and biotech identify targets and predictive biomarkers. Orakl aims to accelerate oncology drug development and reduce clinical trial failures by enabling earlier and more accurate evaluation of drug candidates. Launched in 2023 as a spin-out from the Gustave Roussy Institute, the company is initially focused on colorectal and pancreatic cancers. Orakl raised €3 million in an oversubscribed fundraising round and plans to use the proceeds to launch wet and dry lab capabilities, hire key team members, and execute its first contracts with pharma and biotech partners.

Total raised

$16M

Funding rounds

2

Latest round

Seed

Latest activity

Dec 2024